- Home
- VVPR vs ALXO Comparison
VVPR vs ALXO Comparison
Compare VVPR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVPR
- ALXO
- Stock Information
- Founded
- VVPR 2014
- ALXO 2015
- Country
- VVPR United Kingdom
- ALXO United States
- Employees
- VVPR N/A
- ALXO N/A
- Industry
- VVPR Power Generation
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- VVPR Utilities
- ALXO Health Care
- Exchange
- VVPR Nasdaq
- ALXO Nasdaq
- Market Cap
- VVPR 26.9M
- ALXO 28.3M
- IPO Year
- VVPR 2016
- ALXO 2020
- Fundamental
- Price
- VVPR $4.72
- ALXO $0.46
- Analyst Decision
- VVPR
- ALXO Strong Buy
- Analyst Count
- VVPR 0
- ALXO 6
- Target Price
- VVPR N/A
- ALXO $3.54
- AVG Volume (30 Days)
- VVPR 401.3K
- ALXO 512.2K
- Earning Date
- VVPR 01-01-0001
- ALXO 05-08-2025
- Dividend Yield
- VVPR N/A
- ALXO N/A
- EPS Growth
- VVPR N/A
- ALXO N/A
- EPS
- VVPR N/A
- ALXO N/A
- Revenue
- VVPR $79,000.00
- ALXO N/A
- Revenue This Year
- VVPR N/A
- ALXO N/A
- Revenue Next Year
- VVPR N/A
- ALXO N/A
- P/E Ratio
- VVPR N/A
- ALXO N/A
- Revenue Growth
- VVPR N/A
- ALXO N/A
- 52 Week Low
- VVPR $0.62
- ALXO $0.44
- 52 Week High
- VVPR $6.66
- ALXO $17.50
- Technical
- Relative Strength Index (RSI)
- VVPR 73.57
- ALXO 38.73
- Support Level
- VVPR $2.35
- ALXO $0.41
- Resistance Level
- VVPR $5.00
- ALXO $0.55
- Average True Range (ATR)
- VVPR 0.43
- ALXO 0.05
- MACD
- VVPR 0.13
- ALXO 0.00
- Stochastic Oscillator
- VVPR 87.04
- ALXO 22.76
About VVPR VivoPower International PLC
Vivopower International PLC is a solar power company. It provides energy infrastructure generation, and distribution solutions and is also engaged in the development, construction, and sale of photovoltaic(PV) solar projects. Its operating segments include Solar Development, Critical Power Services, Sustainable Energy Solutions, Electric Vehicles, and Corporate Office. The majority of the firm's revenue is generated from the Electric Vehicles segment. Geographically its key revenue derives from the Netherlands.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.